-
These 22 pharmaceutical companies are bright!
Time of Update: 2021-11-05
List of national technological innovation demonstration pharmaceutical companies that have passed the review and evaluation in 2021CSPC: Two-wheel drive of innovation and internationalizationCSPC: Two-wheel drive of innovation and internationalizationCSPC's revenue and R&D investment (unit: 100 million yuan)CSPC is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs .
-
Nuocheng Jianhua brings the second-generation pan-TRK inhibitor ICP-723 to the Zhongguancun Forum 2021 for the first time
Time of Update: 2021-11-05
Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) will bring the company's self-developed second-generation pan-TRK small molecule inhibitor ICP-723 for the first time at Zhongguancun Forum 2021, and will participate in international technology transactions at the forum Conference "New Technology and New Products First Launch and Promotion Conference" .
-
A large number of pharmacies apply for the "Internet Drug Information Service Qualification Certificate" to prepare for online drug sales
Time of Update: 2021-11-05
Proof of providing Internet drug servicesProof of providing Internet drug servicesRecently, the Hebei Provincial Food and Drug Administration issued an announcement that according to the relevant provisions of the "Internet Drug Information Service Management Measures", after review, Hebei Haishengtang Pharmacy Chain Co.
-
Biopharmaceutical company Oculis announces establishment of Hong Kong office and appointment of global chief medical officer
Time of Update: 2021-11-05
Ruyu Chang will play an important role in the executive management team, strengthen Oculis' existing businesses in China, Europe and the United States, and help the company's global development .
-
Huabei Pharmaceutical's Amoxicillin Sodium and Clavulanate Potassium for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-11-05
On August 26, North China Pharmaceutical issued an announcement stating that it had recently received the "Notice of Approval of Supplementary Drug Application" for Amoxicillin Sodium and Clavulanate Potassium for Injection (0.
To reduce the chance of drug resistance .
-
The national drug counter is here!
Time of Update: 2021-11-05
One week after pharmacies set up the "National Central Procurement Drug Sales Counter", the number of drugs sold increased by 46% on average, and the highest increase was 80% .
-
SHPL-49 injection, a new class 1 chemical drug of Shanghai Hutchison Pharmaceuticals, obtained NMPA and FDA clinical trial approval
Time of Update: 2021-11-04
The SHPL-49 injection was approved for clinical trials in China and the United States, marking the staged success of the collaborative innovation and achievement transformation of Shanghai University of Traditional Chinese Medicine and Shanghai Hutchison Pharmaceuticals .
-
Three quarterly report disclosures are gradually reaching a climax: the performance of pharmaceutical companies is mixed
Time of Update: 2021-11-04
According to the 2021 third quarter report of Zhenghai Biological, the company's main operating income was 301 million yuan, a year-on-year increase of 39.
-
The tens of billions of diabetes drug market will usher in strong competitors
Time of Update: 2021-11-04
According to reports, Microchip's new class 1 diabetes drug "siglita sodium" has been approved recently and is expected to be approved for marketing in the near future .
-
Yasheng Pharmaceutical's new and potent EED inhibitor research results are published on JMC
Time of Update: 2021-11-04
The leading journal in the field, the Journal of Medicinal Chemistry, published an article revealing the potential of the potent oral embryonic ectodermal development protein (EED) inhibitor EEDi-5273 (ie APG-5918), which is expected to regulate tumor epigenetics and tumor microenvironment Overcome tumor drug resistance and achieve complete and lasting tumor regression .
-
New developments in epilepsy drugs: eslicarbazepine's first imitation approved soon
Time of Update: 2021-11-04
In China, the original eslicarbazepine acetate has not been approved for marketing, but the drug has been included in the "Second Batch of Encouraging Generic Drugs List" published on the National Health Commission website in March 2021 .
-
By 2025, the scale of the biomedical industry in Tianjin Binhai New Area will reach 100 billion yuan
Time of Update: 2021-11-04
It is reported that during the "14th Five-Year Plan" period, the biomedical industry in Binhai New Area will promote the construction of the biological manufacturing valley and the characteristic "cell valley" of Beijing-Tianjin-Hebei, focusing on key areas such as synthetic biology, vaccines, cell and gene therapy, and creating biological medicine and chemistry.
-
Clinical trial of AstraZeneca anticancer drug AZD5991 suspended due to cardiac safety risks
Time of Update: 2021-11-04
gov), AstraZeneca has suspended a phase 1 clinical trial of its experimental blood cancer drug MCL-1 inhibitor AZD5991 .
The trial aims to evaluate the efficacy and safety of AZD5991 as a monotherapy or in combination with AbbVie/Roche's listed blood cancer drug Venclexta (venetoclax) in the treatment of relapsed or refractory hematological malignancies .
-
Gao Yaxiang, general manager of Zhejiang Xinlei Compressor unveiled at the 2021 compressed air dual-carbon energy-saving forum
Time of Update: 2021-11-04
To this end, the Shanghai Air Standard Compressor Technology Testing Center and the Shanghai International Biological Fermentation Exhibition Organizing Committee jointly organized this summit forum, and specially invited senior experts from related industries for exchanges and discussions .
-
How to Promote the High-quality Development of Public Hospitals Jilin Province Issues Implementation Opinions
Time of Update: 2021-11-04
，《》（《》）。 《》、、、、、、。，《》， 5 ，，，，、、。 《》： 〔2021〕43 （），，、（），（），、： 《》（〔2021〕18），，，、，，。 、 ，、、、，，，，，，5，，，，、、。 、 （）。3，、，，，，，、。，、、、、，“”。 (2) Strengthen the construction of public hospitals in prefectures an
-
Gansu Provincial Human Resources Examination Center issued a notice: this year's licensed pharmacist exam will be cancelled
Time of Update: 2021-11-04
According to the relevant arrangements of the "Notice of the General Office of the Ministry of Human Resources and Social Security on the 2021 Professional and Technical Personnel Vocational Qualification Examination Work Plan and Related Matters", the 2021 licensed pharmacist vocational qualification examination will be held on October 23 and 24 .
-
From October 20th, the fifth batch of centralized procurement drugs in a batch of provinces will be concentrated
Time of Update: 2021-11-04
Shaanxi The Shaanxi Provincial Medical Insurance Bureau issued a notice on September 10, which clearly stated that the results of the fifth batch of nationally organized drug centralized procurement will be officially implemented in Shaanxi Province from 0:00 on October 20, 2021 .
-
It's time for pharmacies to transform
Time of Update: 2021-11-04
New pharmaceutical retail, relying on the Internet information platform, implements online orders and offline distribution .
The reason why a large number of physical stores will be transformed or closed is because they have not adapted to the rise of new retail models .
-
Localities are vigorously promoting the development of Chinese medicine, internationalization is becoming a major trend
Time of Update: 2021-11-04
In recent years, in order to vigorously promote the inheritance, innovation and development of Chinese medicine in China, the state has issued a series of favorable measures .
-
The development of the domestic pharmaceutical industry continues to improve, and a large number of talents from multinational pharmaceutical companies are turning to local companies
Time of Update: 2021-11-04
Eid, an expert in the medical field, officially announced that he would join Hengrui Medicine in October as executive vice president, chief medical officer and head of global drug development .
